-
2021 ASH third-generation TKI punatinib treatment of CML new progress
Time of Update: 2022-01-09
: Post-hoc analysis of the effect of baseline BCR-ABL1 levels and mutation status on the efficacy of Ponatinib in patients with chronic myeloid leukemia (CML-CP) in the chronic phase of chronic myeloid leukemia (CML-CP) in the 307OPTIC trial OPTIC (Optimizing Ponatinib Treatment in CP-CML, NCT02467270; Ongoing) is a phase II trial that evaluates the safety and effectiveness of Pranatinib in CP-CML patients who are resistant to ≥2 TKIs or have T315I mutations .
-
2021 ASH master talks about Professor Chen Wenming's in-depth interpretation of the progress and application of targeted BCMA therapy in RRMM patients
Time of Update: 2022-01-09
Professor Chen Wenming from the Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, and his team conducted a study (LUMMICAR-1 study) to explore the treatment of relapsed and refractory multiple myeloma (RRMM) with fully human anti-BCMA autologous CAR-T cell CT053 ), and was selected for the 2021 ASH poster presentation.
-
2021 ASH big coffee talks about Professor Zhang Mingzhi: Challenges and research progress of CAR-T treatment of T-ALL/LBL
Time of Update: 2022-01-09
Professor Zhang said that among the dozen or so patients who have been treated, most of the patients participated in the CD7-CAR-T clinical trial after the failure of allogeneic hematopoietic stem cell transplantation and multi-line chemotherapy .
-
Express delivery rate reached 62%, Janssen submitted a bispecific antibody listing application
Time of Update: 2022-01-09
▎The content team editor of WuXi AppTec today, Janssen, a subsidiary of Johnson & Johnson, announced that it has submitted a biologics license application (BLA) for teclistamab to the US FDA for the treatment of relapsed or refractory (R/R) Patients with multiple myeloma (MM) .
-
Retrospective study of new horizons in myeloma: maintenance treatment options after multiple myeloma transplantation
Time of Update: 2022-01-09
A phase I/II study showed that carfilzomib + lenalidomide + low-dose dexamethasone (CRd) is well tolerated and prolonged PFS after induction and maintenance therapy; another phase I/II study It has been shown that the use of carfilzomib + melphalan, ASCT and carfilzomib maintenance treatment in patients with recurrent myeloma brings PFS and OS benefits .
-
Research on the related mechanism of Professor Jin Lu Daratumumab in the treatment of AL amyloidosis
Time of Update: 2022-01-09
Recently, the team of Professor Lu Jin from the Institute of Hematology, Peking University People's Hospital published the latest research results in the Journal of Clinical And Translational Medicine, revealing for the first time the dynamic profile of T cells before and after the treatment of AL amyloidosis with daratumumab .
-
Feast in the clouds, talk about blood together!
Time of Update: 2022-01-09
The conference was chaired by Professor Yang Zhigang from Zhanjiang Central People’s Hospital, Professor Lai Yongrong from the First Affiliated Hospital of Guangxi Medical University, and Professor Yao Hongxia from Hainan Cancer Hospital, and invited top domestic scholars in the field of hematology on hematopoietic stem cell transplantation, cell therapy, leukemia, etc.
-
[Lymphoma Micro-Class 2021ASH Express] Assessment of Quality of Life of Chinese CLL Patients
Time of Update: 2022-01-09
Today I will mainly introduce to you a real-world study on the quality of life assessment of Chinese patients with chronic lymphocytic leukemia (CLL) conducted by our hospital and the Institute of Psychology, Central South University .
-
Ann Hematol: Mortality of acquired thrombotic thrombocytopenic purpura in the pre-kapalizumab era
Time of Update: 2022-01-08
NPV: Negative predictive value Figure 1: ROC curve analysis of the mortality and prognostic factors of 102 patients with autoimmune thrombotic thrombocytopenic purpura for the first time .
-
The domestically produced "three anti-" works!
Time of Update: 2022-01-08
These data show that, as a new type of CD19/CD20 targeting T cell adaptor trispecific antibody, BR110 (CMG1A46) has very good anti-tumor potential, and its clinical development prospects are promising .
-
Lancet Haematol: All-trans retinoic acid increased dose dexamethasone can be used as the first-line treatment for patients with newly diagnosed immune thrombocytopenia
Time of Update: 2022-01-08
Recently, a multicenter, open-label, randomized, controlled, phase 2 trial was published in the journal Lancet Haematol, aiming to evaluate all-trans retinoic acid with increased dose dexamethasone as the first-line treatment for patients with newly diagnosed immune thrombocytopenia The activity and safety .
-
STTT: The domestic multi-center study ORIENT-4 confirmed that the PD-1 inhibitor sintilimab (sintilimab) is effective and tolerable in patients with relapsed/refractory extranodal NK/T cell lymphoma (r/r ENKTL) good
Time of Update: 2022-01-08
Therefore, a number of domestic hospitals jointly launched a multi-center, single-arm phase II study ORIENT-4 (NCT03228836) to evaluate the PD-1 inhibitor sintilimab (sintilimab) in the treatment of relapsed/refractory extranodal NK/T cells Efficacy and safety of patients with lymphoma (r/r ENKTL) .
-
Acute T lymphocytic leukemia with myeloid expression orMPAL dual phenotype?
Time of Update: 2022-01-08
According to MICM (cell morphology, immunology, cytogenetics, molecular biology) test results, most acute leukemias can be divided into acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL), but there are a few acute leukemias ( AL) malignant cells have no clear evidence that their antigen expression is differentiated along a single lineage.
-
Haematol: Daratumumab may be used for multiple refractory autoimmune cytopenias
Time of Update: 2022-01-08
5%]; median age 45 years [range, 34-70]) from six participating centers received daratumumab for refractory ITP (n=5), Acquired Glanzmann syndrome with pre-ITP and normal platelet count (n=1) or warm AIHA (n=2) .
-
The guidelines recommend the "2021 Consensus Guidelines: Diagnosis and Management of Invasive Mycosis Caused by Molds (excluding Aspergillus) in the Department of Hematology/Oncology"
Time of Update: 2022-01-08
Please scan the QR code to download the APP directly Download link: Metz Medicine APP Tip: 78% of users have downloaded Metz Medicine APP , which is more convenient to read and communicate.
-
Nature Biotechnology: Discover a new immunotherapy for the treatment of leukemia
Time of Update: 2022-01-08
December 7, 2021This research develops a new T cell immunotherapy that targets the terminal deoxynucleotidyl transferase (TdT) expressed only in T cells and B cell leukemia cells, but not in normal T cells and B cells.
-
AJH: Patients with myeloproliferative tumors treated with Ruxotinib have an impaired response to the first SARS-CoV-2 vaccination
Time of Update: 2022-01-08
Generally speaking, the degree of specific antibody response (T1 time point) after the first dose of vaccination is measured by the binding antibody unit (BAU)/mL of anti-S and anti-RBD immunoglobulin and the relative index of neutralizing antibody (Figure 1(A))-(C) ), compared with the healthy control group and the ruxo-free group, the number of ruxo patients was significantly reduced .
-
Haemophilia: Elevated endoglin levels in hemophilia patients are associated with angiogenesis-related Angiopoietin 2
Time of Update: 2022-01-07
The study compared the plasma protein levels and mRNA expression of ENG and various angiogenesis-related cytokines in blood samples of 28 hemophilia A or B patients and 29 healthy volunteers .
-
Traditional Chinese medicine can regulate the mechanism of cytosis and play an important role in multi-system diseases
Time of Update: 2022-01-07
Guanxinkang (GXK) is a formula designed by the research group consisting of astragalus, salvia, motherwort, geranium, pinellia, and scallion white, which can improve thoracic aortic disease, increase the phagocytic rate of splenic macrophages, and up-regulate LDLR -/- Protein expression of thrombospondin 1 and TAM receptor (Tyro3/Axl/Mertk) in mice .
-
Intravenous blood glucose <0.3, peripheral blood glucose 5.0, where did the blood sugar go?
Time of Update: 2022-01-07
Hypoglycemia managementRecently, an extremely low blood sugar result has attracted the attention of laboratory teachers.
The result of the patient's peripheral blood sugar at the same time was 5.
